Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Alnylam Receives Intent-to-Grant Notice for European Patent Application

Alnylam Receives Intent-to-Grant Notice for European Patent Application

Apr 23, 2009
Premium

Alnylam Pharmaceuticals this week announced that the European Patent Office has said it intends to grant it a patent broadly covering RNAi therapeutics.

The patent is assigned to the Max Planck Society, the Massachusetts Institute of Technology, and the Whitehead Institute for Biomedical Research and exclusively licensed by Alnylam.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Officially Notified

The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.

Starting With Bit of a Raise

Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.

Harvard, MIT File Lawsuit Against Trump Administration

The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.

Nucleic Acids Research Studies on Molecular Typing, RNA-DNA Hybrids, Protein-RNA Binding Tools

In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.

What's Popular?

In Gene Silencing/Gene Editing

  1. Bacterial Toxin Leads to CRISPR-Free Mitochondrial DNA Base Editing

  2. Computational Tools Help Predict Efficiency, Outcomes of Base Editors

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.